This site is intended for U.S. Healthcare Professionals only.

  • US Full Prescribing Information |
  • Medication Guide |
  • Indication

    Indication

    SOTYKTU is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

    Limitations of Use: SOTYKTU is not recommended for use in combination with other potent immunosuppressants.

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.

Dosing

Patients may take SOTYKTU anywhere, at any time

Managing moderate-to-severe plaque psoriasis can get complicated. With SOTYKTU, patients take a once-daily pill. SOTYKTU can be taken anywhere, at any time that fits best within their daily routine.

THE FIRST AND ONLY ONCE-DAILY ORAL TYK2 INHIBITOR WITH1:

The first once-daily oral TYK2 inhibitor
NO label-required lab monitoring after initial TB evaluation

NO TESTS ARE REQUIRED FOR TREATMENT INITIATION OTHER THAN TB EVALUATION
(unless patients have known or suspected liver disease*)

No required dose titration

NO
DOSE TITRATION OR DOSE ADJUSTMENTS1

NO known drug-to-drug interactions.

NO
KNOWN DRUG-TO-DRUG INTERACTIONS1
Avoid use with live vaccines

Can be taken with or without food

CAN BE TAKEN WITH OR WITHOUT FOOD1

*In patients with known or suspected liver disease, evaluate liver enzymes at baseline and thereafter according to routine patient management.

  • Update immunizations according to current immunization guidelines. Periodically evaluate triglycerides according to clinical guidelines. Not recommended for use in patients with severe hepatic impairment

Tablets should be taken whole.

SOTYKTU tablet is not shown at actual size. For illustrative purposes only.

NDC: 0003-0895-11

TB=tuberculosis; TYK2=tyrosine kinase 2.

Bristol Myers Squibb™ Logo

SOTYKTU, SOTYKTU 360 SUPPORT, and SOTYKTU
logo
are trademarks of Bristol-Myers Squibb Company.

© 2023 Bristol-Myers Squibb Company.

Otezla is a registered trademark of Amgen Inc

1787-US-2200720 12/22

1787-US-2200110 09/22